Summary
Abbott Laboratories (ABT) has announced the successful completion of its acquisition of Exact Sciences Corporation, a significant move that closed on March 23, 2026. This strategic acquisition, executed through a merger agreement finalized on November 19, 2025, integrates Exact Sciences into Abbott's structure as a wholly owned subsidiary. The transaction involved an all-cash payout of $105.00 per share for Exact Sciences common stock, a substantial financial commitment by Abbott. This acquisition is expected to be a transformative event for Abbott, likely bolstering its position in the diagnostics and healthcare markets, particularly in areas where Exact Sciences has a strong presence, such as cancer screening and genomic testing. Investors should closely monitor the integration process and the impact on Abbott's future revenue streams and market share, as this deal represents a major step in the company's growth strategy.
Key Highlights
- 1Abbott Laboratories (ABT) completed the acquisition of Exact Sciences Corporation on March 23, 2026.
- 2The acquisition was structured as a merger, with Exact Sciences now operating as a wholly owned subsidiary of Abbott.
- 3Each share of Exact Sciences common stock was acquired for $105.00 in cash.
- 4The transaction was governed by a Merger Agreement dated November 19, 2025.
- 5Abbott has issued a press release on March 23, 2026, officially announcing the closing of the merger.
- 6The filing includes the Merger Agreement as Exhibit 2.1 and the press release as Exhibit 99.1.